Participants given tirzepatide lowered their HbA1c by a mean 0.77% more than those given a higher dulaglutide dose. More tirzepatide participants hit a weight loss threshold known for disease ...

Australia’s Therapeutic Goods Administration (TGA) has accepted a court-enforceable undertaking from Your Solution ...

With two new lawsuits, Eli Lilly (NYSE: LLY) has escalated its legal campaign against the makers of unauthorized versions of ...

Switching to tirzepatide linked to additional reduction in HbA1c, weight loss compared with escalating dulaglutide. HealthDay News — For patients with inadequately controlled type 2 diabetes ...

Previous studies have shown improved kidney function with other drugs in the same class but this trial is the first to assess tirzepatide's impact on kidney and cardiovascular outcomes in people ...

Opens in a new tab or window Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose.

According to a lawsuit filed by Eli Lilly on Monday, April 7, Premier Weight Loss, a spa based in Lilly's own backyard in Indianapolis, buys autoinjector pens filled with tirzepatide, cracks them ...

Tirzepatide targets two receptors in order to shrink fat cells and reduce the impacts that enlarged fat cells have on heart and kidney health. The drug is approved by the U.S. Food and Drug ...

India's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven ...

India's anti-obesity drug market has surged, growing over fourfold in five years, reaching Rs 576 crore by March 2025.

NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c ...